Scarica l'app Stockscreener
2.57
1.98%
0.05
Pre-mercato:
2.56
-0.010
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$2.52
Aprire:
$2.52
Volume 24 ore:
8.70M
Relative Volume:
1.01
Capitalizzazione di mercato:
$775.90M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-1.7133
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
+8.90%
1M Prestazione:
+45.20%
6M Prestazione:
+66.88%
1 anno Prestazione:
+53.89%
Intervallo 1D:
$2.41
$2.58
Intervallo di 1 settimana:
$2.2408
$2.73
Portata 52W:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
2.57 | 760.81M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific Biosciences showcases HiFi sequencing at FOG2026 in London - Traders Union
Pacific Biosciences stock shows signs of recovery, Canaccord maintains Buy By Investing.com - Investing.com Canada
How The New Price Target Is Reframing The Story For Pacific Biosciences (PACB) - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts - Nasdaq
Pacific Biosciences of California (NASDAQ:PACB) Hits New 52-Week HighTime to Buy? - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 7.9%Still a Buy? - MarketBeat
Here's why you should add PacBio stock to your portfolio - MSN
Volume Summary: Does Erayak Power Solution Group Inc have high return on assetsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $11.11 Million Position in Pacific Biosciences of California, Inc. $PACB - MarketBeat
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know - sharewise.com
Pacific Biosciences Shares Gain Momentum on Strong Preliminary Results and Clinical Adoption - AD HOC NEWS
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 6.6%Time to Sell? - MarketBeat
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 11% Over Last Week - 富途牛牛
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Trading 6.2% HigherStill a Buy? - MarketBeat
Pacific Biosciences of California unveils HiFi sequencing demo at PAG33 - Traders Union
Canada Next-Generation Sequencing (NGS) Market Analysis and - GlobeNewswire
Canada Next-Generation Sequencing (NGS) Market Analysis and Forecast, 2025-2035, Featuring Illumina, Oxford Nanopore Technologies, Pacific Bioscience of California, MGI Tech Co., QIAGEN and More - Yahoo Finance
Pacific Biosciences stock gets Buy rating reiteration from Canaccord By Investing.com - Investing.com Canada
Pacific Biosciences' Preliminary Q4 Revenue Climb 14% On DNA Sequencing System Sales - Nasdaq
PACB: Clinical adoption and SPRQ innovation drive growth, with Europe leading and costs dropping - TradingView — Track All Markets
PACB: Clinical growth, Spark Chemistry, and record consumables drive robust momentum into 2026 - TradingView
PacBio plans collaboration on rare disease therapies with n-Lorem By Investing.com - Investing.com Canada
PacBio (PACB) Advances Childhood Death Research with HiFi Genome Sequencing - GuruFocus
PACB Forecasts Strong FY25 Revenue as Sales Gain Traction - GuruFocus
PacBio Announces Proposed Collaboration with n-Lorem Foundation and EspeRare to Advance Antisense Oligonucleotide Therapies for Rare Genetic Diseases - Quiver Quantitative
PacBio to Support Research on Sudden Unexplained Death in Childhood Using HiFi Whole-Genome Sequencing - Quiver Quantitative
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases - marketscreener.com
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC) - marketscreener.com
New DNA test seeks deeper answers for parents after child deaths - Stock Titan
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
How PacBio (PACB) Is Seeing Its Fair Value Story Shift After ARK’s Share Purchase - Yahoo Finance
PACB Stock Down Despite Q3 Earnings Beat Estimates, Revenues Down Y/Y - MSN
PacBio stock dips post latest launch to expand multiomics capabilities - MSN
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates - MSN
HOKA Shopping Guide: Can Pacific Biosciences of California Inc. stock double in next 5 years - ulpravda.ru
PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities - sharewise.com
Can PacBio’s New CiFi Method Reshape PACB’s Innovation Story and Recurring Revenue Potential? - Yahoo Finance
Can Pacific Biosciences of California Inc. stock deliver consistent earnings growthOptions Play & Short-Term High Return Strategies - ulpravda.ru
What insider trading reveals about Pacific Biosciences of California Inc. stockTrade Exit Summary & Smart Investment Allocation Tips - Улправда
How Pacific Biosciences of California Inc. (P09) stock trades after rate cutsPortfolio Update Report & Reliable Entry Point Alerts - ulpravda.ru
Is Pacific Biosciences of California Inc. stock a defensive play in 20252025 Earnings Impact & Daily Growth Stock Investment Tips - Улправда
What technical charts say about Pacific Biosciences of California Inc. stockJuly 2025 Closing Moves & Free Weekly Watchlist of Top Performers - ulpravda.ru
Can Pacific Biosciences of California Inc. stock double in next 5 yearsJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - ulpravda.ru
PacBio and UC Davis Researchers Introduce CiFi, A New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from A Single SMRT Cell - marketscreener.com
PacBio introduces CiFi method for chromosome-scale genome assembly By Investing.com - Investing.com Canada
PacBio Introduces CiFi: A Breakthrough Method for Chromosome-Scale Genome Assemblies from Limited Sample Material - Quiver Quantitative
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell - marketscreener.com
New DNA mapping method builds full chromosomes from tiny samples - Stock Titan
Will Pacific Biosciences of California Inc. (P09) stock justify high valuationFed Meeting & Expert Curated Trade Ideas - ulpravda.ru
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):